BOSTON, Feb. 26, 2004 -- (PRIMEZONE)
-- NeuroSystems, LLC announced today that it has filed an additional U.S. patent
for its Multimodality NeuroMonitoring technology.
Building on the company's existing base of intellectual property,
the present filing describes a suite of unique, tunable algorithms which analyze
and display higher order relationships between and among basic monitored parameters
such as intracranial pressure (ICP), cerebral blood flow (CBF), blood pressure,
and the partial pressures of oxygen and carbon dioxide.
While neurosurgical monitoring has historically been largely
limited to the measurement of ICP, a rather late stage indicator of the patient's
status and probable clinical outcome, the past decade has seen the introduction
of a number of sensor technologies which permit the monitoring of other important
physical and chemical quantities including CBF, tissue oxygen and carbon dioxide,
pH, temperature, and the concentrations of various metabolites and ions via microdialysis.
According to NeuroSystems, with the recent exception of CBF, there has been little
effort to interrelate these new data in real-time in clinically meaningful ways.
As a result, many potentially important monitored parameters have to date been
underutilized.
By intelligently blending various individual parameters,
the company's first product, NeuroSystems 1™, will provide neurosurgeons
and other clinicians the ability to display important higher order, clinically
relevant neurophysiologic functions including cerebral autoregulation, vasoreactivity
and oxygen metabolism via a series of full-featured clinician displays.
According to Walter Johnson, MD, Associate Professor of Vascular
Neurosurgery at Loma Linda University Medical Center, "Multimodality neuromonitoring
will soon be the standard of care in neurotrauma and cerebrovascular disease critical
care. With the addition of new parameters like oxygen saturation and cerebral
blood flow, we need new ways of looking at these data and their relationship with
other physiologic parameters, continuously and in real-time. "
Rick Cataldo, NeuroSystems' President, added, "It is
clear that the successful integration of new parameters into the neuromonitoring
regime is directly related to the ability to analyze interrelated data and display
data relationships in a clinically useful format. NeuroSystems 1 represents a
decisive step forward in multimodality neuromonitoring."
NeuroSystems' mission is to develop and market intelligent
NeuroMonitoring systems which maximize the clinical value of basic monitored parameters
through real-time calculation, storage and display of clinically relevant derived
parameters and neurophysiologic indicators.
* CAUTION: Investigational Device. Limited by Federal (USA) law to investigational
use.
# # #
